1	
I	

2

Rapid Biphasic Decay of Intact and Defective HIV DNA

Reservoir During Acute Treated HIV Disease

3

Alton Barbehenn¹, Lei Shi², Junzhe Shao², Rebecca Hoh¹, Heather M. Hartig¹, Vivian Pae¹,
Sannidhi Sarvadhavabhatla¹, Sophia Donaire¹, Caroline Sheikhzadeh¹, Jeffrey Milush⁵, Gregory
M. Laird³, Mignot Mathias³, Kristen Ritter³, Michael J. Peluso¹, Jeffrey Martin⁴, Frederick Hecht¹,
Christopher Pilcher¹, Stephanie E. Cohen^{1,6}, Susan Buchbinder⁶, Diane Havlir¹, Monica
Gandhi¹, Timothy J. Henrich⁵, Hiroyu Hatano¹, Jingshen Wang², Steven G. Deeks¹, and Sulggi
A. Lee^{*1}

10

¹Department of Medicine, Division of HIV, Infectious Diseases & Global Medicine, University of
 California San Francisco, San Francisco, CA 94110, USA. ²Department of Biostatistics,
 University of California Berkeley, Berkeley, CA 94110, USA. ³AccelevirDiagnostics, Baltimore,
 MD 21202, USA. ⁴Department of Biostatistics & Epidemiology, University of California San
 Francisco, CA 94158, USA. ⁵Department of Medicine, Division of Experimental Medicine,
 University of California San Francisco, San Francisco, CA 94110, USA. ⁶San Francisco
 Department of Public Health, San Francisco, CA 94102, USA.

18

19 [#]Co-Lead Authors: Alton Barbehenn and Lei Shi

^{*}Corresponding Author: sulggi.lee@ucsf.edu

21 ABSTRACT

22 Despite antiretroviral therapy (ART), HIV persists in latently-infected cells ("the reservoir") which 23 decay slowly over time. Here, leveraging >500 longitudinal samples from 67 people with HIV 24 (PWH) treated during acute infection, we developed a novel mathematical model to predict 25 reservoir decay from peripheral CD4+ T cells. Nonlinear generalized additive models 26 demonstrated rapid biphasic decay of intact DNA (week 0-5: $t_{1/2}$ ~2.83 weeks; week 5-24: 27 t_{1/2}~15.4 weeks) that extended out to 1 year. These estimates were ~5-fold faster than prior decay estimates among chronic treated PWH. Defective DNA had a similar biphasic pattern, but 28 data were more variable. Predicted intact and defective decay rates were faster for PWH with 29 30 earlier timing of ART initiation, higher initial CD4+ T cell count, and lower pre-ART viral load. 31 These data add to our limited understanding of HIV reservoir decay at the time of ART initiation, 32 informing future curative strategies targeting this critical time.

33

34 Abstract Word Count (limit 150): 148

36 **Title Word Count** (max 15): 15

37 Manuscript Word Count (5,000; Methods 3,000 words): 4,938

38 Keywords: acute HIV; antiretroviral therapy (ART); HIV reservoir decay; pre-exposure
 39 prophylaxis (PrEP)

40 **CONFLICTS:** The authors do not have a commercial or other association that might pose a 41 conflict of interest.

42 FUNDING: This work was supported in part by the National Institutes of Health: K23GM112526 43 (SAL), the DARE Collaboratory (UM1AI164560; SGD), the AccelevirDx HIV Reservoir Testing 44 Resource (U24AI143502; GML), and NIH/NIAID R01A141003 (TJH). This work was also 45 supported by the amfAR Research Consortium on HIV Eradication a.k.a. ARCHE (108072-50-RGRL; SGD), the Bill & Melinda Gates Foundation (INV-002703; SGD), and investigator-46 47 initiated research grants from ViiV Healthcare (A126326; SAL) and Gilead Sciences (IN-US-236-1354; SAL). The content of this publication does not necessarily reflect the views or policies 48 49 of the Department of Health and Human Services, the San Francisco Department of Health, nor does mention of trade names, commercial products, or organizations imply endorsement by the 50 51 U.S. Government. The funders had no role in study design, data collection and analysis, 52 decision to publish, or preparation of the manuscript.

53 Previous presentation: Preliminary data were presented in July 2023, as a poster presentation
54 at the International AIDS Society (IAS) conference in Brisbane, Australia.

Reprints: Reprint requests can be directed to Dr. Sulggi Lee, the corresponding author (contactinformation above).

57 Acknowledgements:

58 The authors wish to acknowledge the participation of all the study participants who contributed 59 to this work as well as the clinical research staff of the UCSF Treat Acute HIV and SCOPE

medRxiv preprint doi: https://doi.org/10.1101/2024.03.27.24304867; this version posted August 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

60 cohorts who made this research possible. All funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All authors 61 provided critical feedback in finalizing the report. SGD, HH, and SAL conceived and designed 62 63 the study. SGD, HH, and SAL obtained funding to support the clinical enrollment of study 64 participants, and SAL and SGD obtained funding to support characterization of the HIV 65 reservoir. SEC, SB, DH, and MG facilitated coordination with San Francisco Department of 66 Public Health and Ward 86 clinical services to link patients into care and provided critical feedback on the clinical management of acute HIV. SAL, RH, SGD, TJH, HMH, SS, SD, and VP 67 coordinated the collection, management, and quality control processes for the clinical data, and 68 SAL, SGD, JM, FH, and CP provided biospecimens. JM and TJH performed biospecimen 69 70 processing, GML, MM, and KR performed the HIV reservoir assays. LS developed the initial 71 decay models, under the guidance of SAL and JW, and AB and SAL further modified these 72 models under the guidance of JW, LS, and JS. GML, MM, KR, LS, JS, JW, and SAL analyzed 73 the HIV reservoir data. AB, SAL, LS, JS, JW, SS, SD, VP, and CS performed data visualization 74 for the manuscript. SAL and AB wrote the report with critical feedback from LS, JW, and the 75 additional authors.

76 INTRODUCTION

While antiretroviral therapy (ART) is able to suppress virus to undetectable levels, virus 77 rapidly rebounds from latently-infected cells ("the HIV reservoir") within weeks of ART 78 interruption and is thus, not a cure.¹⁻⁸ Thus, a major goal is to eradicate and/or accelerate the 79 80 decay of the reservoir in order to achieve clinical remission. However, HIV cure trials to date have largely failed to demonstrate a clinically meaningful reduction in the size of the HIV 81 reservoir and/or lead to sustained ART-free remission.⁹⁻¹² The majority of these trials have 82 included people with HIV (PWH) treated during chronic infection long after reservoir 83 establishment (i.e., several years after initiating ART).¹³⁻¹⁸ Recent combination trials (e.g., 84 broadly neutralizing antibodies given with ART) have yielded more promising results, and a few 85 participants have demonstrated extended post-intervention viral control.¹⁹⁻²¹ but the mechanisms 86 87 by which these participants have enhanced viral control remain unclear.

88 Individuals who initiate ART "earlier" (<6 months after infection) are more likely to become "post-treatment controllers" (PTCs), demonstrating ART-free viral control after a period 89 of initial ART suppression.²² PWH treated during chronic HIV often have larger reservoirs²³⁻³⁰ 90 and exhausted/dysfunctional immune responses³¹⁻³³ (due to prolonged periods of untreated HIV 91 92 infection). Thus, different host factors, such as timing of ART initiation, initial CD4+ T cell count, or pre-ART HIV viral load, may have profound impact on HIV reservoir decay rates, and yet 93 94 there are limited reservoir decay modeling studies accounting for these factors. While there have now been a handful of studies modeling how quickly the HIV reservoir decays during 95 prolonged ART (~20 years).³⁴⁻³⁷ there have been fewer studies modeling decay rates after acute 96 treated HIV.³⁸⁻⁴⁰ and none directly performing mathematical modeling of HIV intact and defective 97 DNA decay. 98

Here, leveraging >500 longitudinal blood samples, we developed a novel mathematical
 model of reservoir decay among 67 participants from the UCSF Treat Acute HIV cohort initiating
 ART <100 days of HIV infection.⁴¹ We fit various mono-, bi-, and triphasic decay curves for both

102 HIV "intact" (infected cells harboring intact viral sequences able to produce infectious virions) 103 and "defective" (the majority of the HIV reservoir but incapable of producing infectious virions) DNA, and we observed biphasic decay patterns for both measures. Furthermore, both HIV 104 105 intact and defective DNA decay rates were significantly faster among PWH with known clinical 106 factors associated with enhanced host viral control: higher initial CD4+ T cell count, earlier initiation of ART, and lower pre-ART viral loads.^{23,24,34,42,43} As further validation of our 107 108 mathematically modeling approach, we also fit decay models for plasma HIV RNA ("viral load" measured at each study visit using a standard clinical assay with limit of detection < 40109 110 copies/mL). We observed a triphasic decay of plasma HIV RNA, similar to prior reports among PWH initiating ART.^{3,4,40} Our data are the first to our knowledge to describe a predictive 111 112 mathematical model quantifying decay rates of HIV intact and defective DNA during acute 113 treated HIV.

114

115 **RESULTS**

116 Characteristics of study participants

117 A total of 67 adults (83% of those screened) with a new diagnosis of acute HIV (<100 118 days between HIV infection to ART initiation date) were included in the study (Table 1, **Supplementary Fig. 1**).⁴⁴ All 67 participants completed monthly follow-up visits in the study for 119 120 the full 24 weeks. A large proportion (65.7%) of participants were co-enrolled in our longitudinal UCSF SCOPE HIV cohort and remained in study beyond 24 weeks, with study visits 121 approximately every 3-4 months. The median follow-up for our cohort was 0.81 (interguartile 122 range = 0.47-1.66) years. We calculated the estimated date of detected infection (EDDI) for 123 each participant using an algorithm^{45,46} successfully applied to other acute HIV cohorts^{38,39} 124 (Supplementary Fig. 2). We also estimated Fiebig stage^{47,48} for each participant, an older but 125 often cited method for staging recency of HIV infection (Fig. 1). Consistent with our San 126 Francisco-based study population, participants were mostly male (97%) and reflected local and 127

national racial/ethnic trends of higher incident acute HIV in these populations (Fig. 1).⁴⁹ 128 129 Baseline study visit HIV-1 antigen/antibody (Architect) and HIV-1 antibody (Geenius) testing demonstrated 27% and 28% false negative/indeterminate rates (Supplementary Fig. 3), 130 131 respectively, consistent with our San Francisco Department of Public Health (SFDPH) reported estimates for new acute HIV diagnoses.⁵⁰ Genotype data (Monogram) were available for a 132 subset of 57 participants; 77% had wild-type HIV, 9% had M184V/I mutations (all were reported 133 134 among participants citing prior and/or current pre-exposure prophylaxis [PrEP] use), and 14% had evidence of possible partner-transmitted resistance mutations (based on referral of newly 135 diagnosed partners within our cohort and/or SFDPH partner tracing⁵⁰). 136

Our cohort also reflected a high proportion of self-reported prior PrEP use (42% ever 137 use, 20% use in the past 10 days), reflecting San Francisco's early and widespread adoption of 138 PrEP.⁵⁰ All PrEP reported in this study was oral PrEP with tenofovir disoproxil 139 140 fumarate/emtricitabine (TDF/FTC), as this was the only form clinically available during the study 141 period. Among individuals reporting overlapping PrEP use within 10 days of their EDDI, six participants had probable HIV acquisition while on PrEP (median baseline $log_{10}HIV RNA = 2.2$ 142 143 copies/mL, ~3 log₁₀ lower than those not reporting PrEP overlap) (**Table 1, Supplementary Fig.** 4), including one participant⁵¹ who may have acquired HIV in the setting of therapeutic PrEP 144 concentrations (confirmed by plasma and hair ART concentrations). 145

146

147 Rapid biphasic decay of HIV intact and defective DNA

Overall, after fitting various mono-, bi-, and triphasic decay curves using semiparametric generalized additive models, we found that a biphasic decay pattern with an inflection point (τ) = week 5 best fit the data for HIV intact and defective DNA (**Figs. 2-3, Supplementary Fig. 5**). Validation of these models against the observed data showed good model performance (**Fig. 4, Supplementary Figs. 6-7**) and that HIV intact and defective DNA decay patterns significantly

predicted faster decay rates (Figs. 5-6) for participants with known clinical factors associated
 with smaller HIV reservoir size.^{23,24,34,42,43}

First, we modeled HIV intact and defective DNA using a linear effect of time on ART 155 (which assumes a constant rate of change regardless of the duration of viral suppression). 156 157 However, since we observed evidence of nonlinearity, we fit nonlinear generalized additive models to better estimate HIV intact and defective DNA decay patterns. For all models, we 158 159 tested clinical factors of age, pre-ART CD4+ T cell count, pre-ART viral load, and timing of ART initiation for inclusion as potential covariates. We found that both HIV intact and effective DNA 160 were well described by a biphasic model, comparing Akaike information criteria (AIC) (Fig. 2a) 161 and thus was chosen over a triphasic model since comparing the minimum predicted mean 162 absolute error (MAE) using leave-one-out cross-validation and/or the minimum predicted mean 163 164 squared error (MSE) (Fig. 2b), suggested similar inflection points. For HIV intact DNA, the first 165 and second inflection points were similar, suggesting that a single inflection point - i.e., a biphasic model - adequately described the data, and for HIV defective DNA, since the first 166 inflection point was close to zero, this again suggested that a biphasic model well described the 167 data. We then further determined that the inflection point of τ =5 weeks, after comparing MAEs 168 and MSEs, was optimal for both HIV intact and defective DNA (Fig. 3, Supplementary Fig. 5). 169 170 Since we found that several key clinical factors (previously associated with HIV reservoir size initiation^{23,24,34,42,43}) were strongly associated with HIV DNA decay rates (Figs. 5-6), all final 171 172 models included terms for initial CD4+ T cell count, pre-ART viral load, and timing of ART initiation. 173

Our final biphasic decay model of HIV intact DNA demonstrated a rapid $t_{1/2}$ ~2.83 (95%CI = 2.39-3.27) weeks for the first ~5 weeks of AR, followed by a slower second decay phase with a $t_{1/2}$ ~15.4 (95%CI = 12.0-21.9) weeks (**Supplementary Table 1**). HIV defective DNA had a similar pattern, with an initial rapid decay ($t_{1/2}$ ~1.36, 95%CI = 1.17-1.55 weeks), followed by a slower decay, but the change in decay was not statistically significantly given the large

variability in HIV defective DNA during this second phase (Fig. 4). Interestingly, we observed a
significantly faster decay of HIV defective vs. intact DNA during the first phase (p<1e-16) (Fig.
4). While the reasons for this are unclear, given the frequency of our sampling at these acute
HIV timepoints, our observation may potentially be due to (1) a true biological phenomenon
uniquely captured by our frequent early sampling and/or (2) reflect unique properties of the
IPDA (see Discussion).

185 Our final models also demonstrated significantly faster decay rates with clinical factors associated with smaller reservoir size (Figs. 5-6). For example, our models estimated that for 186 HIV intact DNA, for each week earlier that ART was initiated, the t_{1/2} was predicted to be 187 reduced by ~0.0827 (95%CI = 0.0203-0.145) and by ~1.08 (95%CI = 0.316-1.84) during the 188 189 second phase (Supplementary Table 3). Similarly, our models predicted that higher initial 190 CD4+ T count and lower pre-ART HIV RNA predicted significantly faster HIV intact and 191 defective decay rates (Supplementary Table 4). Further validation using fitted spline models 192 again demonstrated that higher initial CD4+ T count and lower pre-ART HIV RNA predicted faster HIV intact and defective DNA decay rates (Supplementary Fig. 10). For example, a 193 participant with an initial CD4+ T cell count of 900 cells/mm³ was predicted to have ~10 times 194 faster decay of HIV intact DNA than a participant with an initial CD4+ T cell count of 300 195 cells/mm³. Similar patterns were observed for HIV defective DNA, but the fitted splines were 196 197 less linear.

While were unable to perform adjusted analyses for other important clinical factors such as gender and race/ethnicity given the small sample sizes in our study (**Table 1**), we did perform sensitivity analyses focusing on the small number of cisgender and transgender women, as well as the small numbers of PWH reporting PrEP use within 10 days of HIV diagnosis. These analyses demonstrated that results were overall relatively unchanged and that these participants did not necessarily fall in the lower range of reservoir measurements (**Supplementary Fig. 8**). Furthermore, to ensure that the selected inflection point of $\tau = 5$ weeks

205 was not influenced by potential outlier data, we performed three different sensitivity analyses 206 excluding participants for whom HIV reservoir measures might fall on the higher and/or lower range of values: (1) individuals reporting prior PrEP use within 10 days of HIV infection, (2) 207 participants with plasma viral load "blips" (defined as a one-time viral load >1000 copies/mL or 208 209 two consecutive viral loads >100 copies/mL between weeks 0-24), and (3) participants with 210 sudden increases in HIV intact DNA (defined as >50% increase between two consecutive measurements during weeks 0-24). These sensitivity analyses demonstrated that $\tau = 5$ weeks 211 remained a reasonable choice for the model's inflection point (Supplementary Fig. 9) and that 212 213 the estimates were overall unchanged after exclusion (Supplementary Table 2).

214

215 Triphasic decay of plasma HIV RNA

As further validation of our mathematical modeling approach, we also fit decay models 216 for plasma HIV RNA. Plasma HIV RNA ("viral load") was measured at each study visit using a 217 218 standard clinical assay (Abbott Real Time PCR assay, limit of detection < 40 copies/mL). We 219 again fit various mono-, bi-, and triphasic models, and a triphasic decay model best fit these data with inflection points at 0.5 and 4 weeks (Supplementary Fig. 11). Our findings are 220 221 consistent with prior published work describing triphasic decay of plasma HIV RNA in treatment naïve PWH initiating integrase inhibitor-based therapy.⁵² Our final adjusted models predicted a 222 rapid initial decay ($t_{1/2} \sim 0.659$, 95% CI = 0.541-0.778 days), a second decay ($t_{1/2} \sim 4.93$, 95% CI 223 224 = 3.98-5.89 days), with no significant decay during the third phase (Supplementary Table 5), closely mirroring prior reported estimates describing a $t_{1/2}$ = 1.14, 9.19, and 340 days, 225 respectively.⁵² As expected, we observed that the majority of our cohort had undetectable 226 227 plasma viremia by a median of 4.14 weeks, consistent with viral suppression rates among treatment naïve PWH initiating integrase inhibitor-based ART.^{53,54} Similar to our approach used 228 for our HIV DNA decay models, we validated our final triphasic plasma HIV RNA decay model 229 230 by comparing predicted vs. observed values and found that the model produced unbiased

estimates across a range of plasma HIV RNA values (**Supplementary Fig. 12**). We again found that known clinical factors associated with reservoir size –e.g., initial CD4+ T cell count and earlier timing of ART initiation –were also associated with accelerated decay rates (**Supplementary Figs. 13-15**).

235

236 **DISCUSSION**

237 Leveraging >500 longitudinal blood samples from the UCSF Treat Acute HIV cohort, we performed mathematical modeling and demonstrated a rapid biphasic decay of HIV intact and 238 defective DNA. Our estimates for HIV intact DNA decay were significantly faster (~5-fold) 239 compared to prior estimates from chronic treated³ PWH initiating ART. Furthermore, clinical 240 factors associated with smaller HIV reservoir sizes (e.g., earlier timing of ART initiation, higher 241 242 initial CD4+ T cell count, and lower pre-ART viral load) predicted faster decay rates of both HIV 243 intact and defective DNA. We further validated our modelling approach by fitting plasma HIV RNA decay rates, and we observed a triphasic decay pattern, consistent with prior estimates.⁵² 244 245 Our mathematical modeling approach may serve as a meaningful way to predict expected 246 decay rates after ART initiation and the potential impact of clinical factors that may differ when comparing across global HIV cohorts that may also have different host genetics, HIV-1 247 subtypes, etc. This approach may also help inform the design of future HIV cure trials, e.g., to 248 249 predict optimal timeframes during which an intervention may have the greatest impact on accelerating reservoir decay and/or limiting reservoir establishment. 250

Our findings compare to several key prior modeling studies of HIV reservoir decay,^{3,55-58} all of which fit mostly unadjusted fully parameterized mixed effects models but still lend support to our findings. For example, we observed an initial rapid HIV intact DNA decay rate of $t_{1/2}$ of ~2.83 weeks (~0.71 months), followed by a slower second phase with a $t_{1/2}$ ~15.4 weeks (~3.9 months). Strikingly, this first phase decay estimate is nearly identical to prior reports in chronic treated PWH initiating ART ($t_{1/2} = 0.43$ months),³ but our estimates for the second phase of

decay were ~5-fold faster than estimates from this other study ($t_{1/2}$ = 19 months), well below 257 their confidence limits (8.23-43.7 months).³ Our faster rate of HIV intact DNA decay during this 258 second phase are unclear but may potentially be due to true biological differences (e.g., less 259 260 exhausted immune cells compared to chronic treated PWH^{59,60}) or reflect greater precision in 261 estimating decay rates from our frequent sampling (every 2-4 weeks). The initial rapid decay of HIV-infected cells after ART initiation is thought to be largely due to clearance of free virions and 262 death of productively infected cells.^{3,4,52,61,62} We estimated similar first phase decay rates as 263 those previously reported in chronic treated PWH initiating ART,³ suggesting that death of 264 productively infected cells, regardless of timing of ART initiation, may indeed be driving the first 265 phase decay estimates. Furthermore, plasma (cell-free) HIV RNA correlates with the frequency 266 of productively infected CD4+ T cells;⁶³ our plasma HIV RNA decay estimates provide further 267 268 support as these estimates are again consistent with prior reported clearance rates of productively infected CD4+ T cells ($t_{1/2} \sim 0.7$ days).⁶⁴ Meanwhile, the second phase of reservoir 269 270 decay after ART initiation is thought to represent a "contraction phase" when activated cells transition from an effector to a memory phenotype with ART-mediated antigen reduction.⁶⁵⁻⁶⁷ 271 272 This second phase is thought to be largely driven by death of longer-lived memory cells.^{68,69} 273 Indeed, if we extrapolate the second phase of our HIV intact DNA model, we estimate that PWH who delay ART initiation to ~56 weeks after HIV infection have a predicted $t_{1/2}$ that is 274 comparable to the (slower) second phase decay reported in chronic treated PWH.³ Our data 275 suggests that - especially during this second phase of decay - that curative interventions given 276 during this critical window of time may have the potential to significantly reduce the 277 establishment of these long-lived memory cells. 278

Our data are also consistent with findings from two prior acute HIV cohorts^{38,58} that did not measure IPDA (HIV intact and defective DNA) but did measure HIV total, integrated DNA, and 2-LTR DNA by real-time PCR^{70} and also performed the quantitative viral outgrowth (QVOA^{25,68,71}) and multiply spliced tat/rev (TILDA⁷²) assays. One of these studies by Massanella

283 and colleagues performed mathematical modeling and also demonstrated biphasic decays of HIV total, integrated, and 2-LTR DNA, with a similar inflection point (6 weeks).⁵⁸ While they were 284 unable to report decay models for QVOA or TILDA (likely due to the low frequency of HIV-285 infected cells despite the large number of input cells,^{73,74} which may have precluded more 286 287 complex decay modeling), their estimates for HIV total, integrated, and 2-LTR decay rates closely compare to our estimates for defective DNA. The population of HIV-infected cells 288 289 generally falls into three broad categories: (1) truly "intact" proviruses, (2) "partially defective" proviruses that can produce defective HIV RNA/proteins, which, despite being unable to 290 produce virus, can still lead to immunogenic/cytopathic effects,⁷⁵ and (3) truly "inert" proviruses 291 that express no HIV RNA or proteins. While the assays in this other study did not specifically 292 discriminate intact from defective viral sequences, since the majority of the HIV reservoir 293 consists of defective provirus⁷³ and since the majority of infected cells in acute PWH consist of 294 these highly unstable unintegrated linear HIV DNA (with an estimated half-life of ~2 days),⁷⁶ the 295 296 overlap in our modeling results may suggest an overlap in the population of HIV-infected cells 297 captured by our respective assays.

Finally, it is important to note that the decay rates described here are likely 298 299 complementary to, but not the same as, decay rates described in several long-term ART studies.^{34-37,71,77} First, these long-term ART studies (in chronic treated PWH) did not sample 300 301 participants at the time of ART initiation and had less frequent sampling over longer periods of ART suppression.^{34-36,57} Overall, these studies described a biphasic decay (inflection point ~7 302 vears of ART) with a $t_{1/2}$ ~44 months for HIV intact DNA^{71,77} and found that HIV intact DNA 303 decayed faster than defective DNA, presumably due to preferential clearance of intact, or 304 "replication-competent", provirus during long-term ART.^{34-36,57,78,79} However, HIV intact DNA 305 306 decay rates have also been shown to plateau or even an increase in some individuals during prolonged ART.^{36,57} Our biphasic model identified a somewhat surprising finding that HIV 307 defective DNA decayed faster than HIV intact DNA during the first phase. The reasons for this 308

medRxiv preprint doi: https://doi.org/10.1101/2024.03.27.24304867; this version posted August 22, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

309 are unclear but may reflect true biological phenomena uniquely captured by our frequent early sampling and/or unique properties of the IPDA. Since the majority of the HIV reservoir consists 310 of defective provirus,⁷³ estimates of HIV total, integrated, and 2-LTR DNA decay rates from the 311 study by Massanella et. al., ($t_{1/2}$ = 14.5, 14.1, and 30.5 days, respectively⁵⁸) are largely 312 313 consistent with our estimates of defective DNA decay rates ($t_{1/2}$ =9.5 days) during the first phase of decay, suggesting a potential true biological phenomena that warrants further study. 314 315 Alternatively, a second possibility is that our observations reflect some misclassification of HIV "intact" provirus (i.e., since the IPDA targets just two regions of the HIV genome to define 316 "defective" provirus⁸⁰). However, Reeves and colleagues recently performed detailed validation 317 318 experiments (e.g., using quantitative viral outgrowth assay and near full-length sequencing) and showed that the rate of misclassification is <5% with the IPDA.⁵⁵ suggesting that this degree of 319 320 misclassification alone would be unlikely to fully explain our findings.

321 Our study has several limitations that deserve mention. While we leveraged several hundred longitudinal blood samples from acute treated PWH, we did not model the HIV tissue 322 reservoir; our tissue studies are currently underway but will be limited in the number of 323 longitudinal timepoints to perform similar detailed modeling. Since the peripheral HIV reservoir 324 largely reflects proviruses originating from the tissue reservoir,^{38,81-83} tissue reservoir decay 325 estimates in ours as well as other studies should be modeled in parallel with the more frequently 326 327 sampled peripheral reservoir decay estimates in future work. We performed IPDA, which, while highly scalable for a large number of samples, less accurately quantifies the replication-328 329 competent reservoir compared to near-full length proviral sequencing or QVOA. Nonetheless, HIV intact DNA measured by IPDA closely reflect results from these other assays, even 330 considering the known enrichment of integrated forms of HIV DNA observed in acute PWH.³⁸ As 331 332 with all molecular assays for HIV, certain polymorphisms at primer or probe binding sites can impact IPDA assay performance. We observed IPDA signal failure for 6 participants (8.9%) - a 333 rate consistent reports from large HIV cohorts from North America and Europe where subtype B 334

predominates (6-7%).^{34,84} We also did not measure changes in clonal landscape (e.g., HIV 335 336 integration). The clonal landscape at the time of acute HIV is extremely diverse, and we 337 hypothesize that this effect is more likely to have greater higher impact after longer duration of ART suppression. Future models should include these parameters to formally test this 338 339 hypothesis. Finally, there are few highly characterized acute HIV cohorts to date, and each 340 study possesses unique host and viral characteristics making direct cross-cohort comparisons challenging. Our study included mostly men who have sex with men and HIV-1 subtype B. It will 341 342 be critical to validate our HIV reservoir decay models in global populations with distinct host 343 genetic ancestry, HIV-1 subtypes, and clinical features to facilitate cross-cohort comparisons and inform future HIV cure trial design and interpretation. 344

The long-lived latent reservoir is a key defining target for HIV cure, but how and where 345 346 these cells then become "the long-lasting latent reservoir" remains unclear. Even in reservoir 347 decay studies analyzing data out to 20 years of ART suppression, decay patterns are not broadly generalizable.^{36,57} Thus, there is a critical need for a scalable approach to broaden our 348 349 understanding of HIV reservoir decay patterns across a global population of PWH, ideally 350 aligning study designs and assays and performing meta-analyses, including how key clinical 351 factors such as the timing of ART initiation, initial CD4+ T cell count, and pre-ART viral load 352 influence decay rates.

353

354 METHODS

355 Study participants

Individuals with newly diagnosed acute (<100 days) from HIV infection were enrolled in the UCSF Treat Acute HIV cohort between December 1, 2015 to November 30, 2020 and coenrolled in the UCSF SCOPE HIV cohort, an ongoing longitudinal study of over 2,500 PWH. Eligible participants were provided same-day ART initiation with tenofovir/emtricitabine

(TDF/FTC, then TAF/FTC once available in 2016) + dolutegravir (DTG) and linked to clinical 360 care.⁵⁰ Individuals reporting concomitant PrEP use (<100 days from any potential exposure to 361 HIV by history and/or clinical test results) were also started on darunavir+ritonavir (DRV/r) as a 362 363 fourth drug, which was continued until confirmation of baseline HIV genotyping test results 364 (Monogram Biosciences, South San Francisco, CA, U.S.A.). Additional ART changes necessary for clinical care (e.g., laboratory abnormalities, drug-drug interactions, and/or participant 365 preference) were honored and adjusted during the period of study. Participants signed a release 366 367 of information which allowed clinical data extraction to determine prior HIV negative test results from the SFDPH, as well as additional HIV test results. 368

369 Study participants were seen for monthly study visits for the first 24 weeks (including an 370 additional week 2 visit to confirm HIV test results from baseline visit) and then every 3-4 months thereafter. Inclusion criteria for the study were prior HIV negative testing within the last 90 days, 371 laboratory-confirmed HIV-1 infection by antibody/antigen and/or plasma HIV RNA assay, and 372 373 willingness to be participate in the study for at least 24 weeks. Participants with severe renal or 374 hepatic impairment, concurrent treatment with immunomodulatory drugs, or exposure to any immunomodulatory drugs in the preceding 90 days prior to study entry, pregnant or 375 376 breastfeeding women, or participants unwilling to agree to the use a double-barrier method of 377 contraception throughout the study period, were excluded. For each study participant, the 378 estimated date of detected HIV infection (EDDI) was calculated using the Infection Dating Tool (https://tools.incidence-estimation.org/idt/).⁴⁵ At each visit, detailed interviews included guestions 379 medications, medication adherence, 380 regarding current intercurrent illnesses. and 381 hospitalizations were performed. In addition, peripheral blood sampling at each visit was 382 performed to measure plasma HIV RNA (Abbott Real Time PCR assay, limit of detection <40 copies/mL), CD4+ T cell count, and clinical labs (complete blood count, metabolic panel). All 383

participants provided written informed consent, and the institutional review board of UCSF
 approved the research.

386

387 HIV reservoir quantification

388 The frequencies of HIV intact and defective (3' and 5') DNA were quantified using the intact proviral DNA assay (IPDA).⁸⁵ CD4+ T cells were isolated from cryopreserved PBMCs 389 390 (EasySep Human CD4+ T cell Enrichment Kit, Stemcell Technologies), with cell count, viability, and purity assessed by flow cytometry. Negatively selected CD4+ T cells were recovered 391 (median cells = 2×10^6 with median viability = 97%) and genomic DNA extracted using the 392 393 QIAamp DNA Mini Kit (Qiagen). DNA concentration and quality were determined by fluorometry 394 (Qubit dsDNA BR Assay Kit, Thermo Fisher Scientific) and ultraviolet-visible (UV/VIS) 395 spectrophotometry (QIAxpert, Qiagen). The frequency of intact provirus was determined using 396 two multiplex digital droplet polymerase chain reaction (ddPCR) assays performed in parallel: 397 (1) the HIV-1 Proviral Discrimination reaction which distinguishes intact from defective provirus 398 via two strategically placed amplicons in HIV psi and RRE regions as well as a hypermutation 399 discrimination probe, and (2) the Copy Reference/Shearing reaction, which quantifies DNA shearing and input diploid cell equivalents using the human RPP30 gene.⁸⁵ All ddPCR reactions 400 were assembled via automated liquid handles to maximize reproducibility and analyzed using 401 402 the BioRad QX200 AutoDG Digital Droplet PCR system (BioRad). Up to 700 ng of genomic DNA were analyzed per reaction, and final input DNA concentrations were dependent upon 403 404 recovered DNA concentrations. Samples were batch processed and analyzed, including negative controls from uninfected donors and J-Lat full-length clone 6.3 (E. Verdin, Gladstone 405 Institutes and UCSF, San Francisco, CA, USA) cells as positive controls. Across >500 IPDA 406 measurements, we interrogated a median of 4.8 x 10⁵ CD4+ T cell genomes per assay and 407 408 observed a median DNA shearing index (DSI) of 0.40.

409

Statistical Methods 410

411

We developed a novel semiparametric biphasic decay model to estimate the HIV DNA reservoir size over time in log₁₀ copies per 10⁶ CD4+ T cells as 412

$$\log_{10}(I_{it}) \sim f_1(T_{it}; \tau, \beta_1, \beta_2) + E_i \cdot f_1(T_{it}; \tau, \beta_3, \beta_4) + f_2(C_i) + f_3(V_i) + \mu_i, \#(1)$$

413 where in I_{it} represents either the HIV intact or defective DNA reservoir size, of the *i*-th 414 participant at t-th visit. The number of weeks since ART initiation is denoted T_{it} . The model additionally accounts for baseline clinical information defined as the initial CD4+ T cell count, C_i , 415 416 pre-ART viral load, V_i , and the estimated time between HIV infection and ART initiation, E_i . The 417 delay in ART initiation was centered to have a mean of zero prior to analysis; this offset was 418 approximately 60 days in our cohort. Participant-level random effects, μ_i , are also included. Building on existing models,^{3,57} we parameterized the decay as a continuous, linear spline with a 419 at τ : $f_1(T_{it}; \tau, \beta_1, \beta_2) = \beta_1 \cdot \min\{T_{it}, \tau\} + \beta_2 \cdot \max\{T_{it} - \tau, 0\}$. Under 420 single knot this parameterization, β_1 and β_2 represent the decay rate before and after τ , respectively. For 421 triphasic models, the decay was modeled as a continuous, linear spline with knots at τ_1 and τ_2 . 422 423 For monophasic models, the decay was modeled as a linear function of time. The same spline parameterization and inflection point(s) were used to model the time on ART and interaction 424 between time on ART and delay in ART initiation; different slopes were estimated for these two 425 426 terms. Cubic splines were used for both $f_2(C_i)$ and $f_3(V_i)$. After fixing the inflection point(s), 427 model estimation was performed using the mgcv (v1.9-1) package in R (4.3.1). A two-sided Welch's t-test was used to compare decay rate estimates across models. 428

429 Regardless of the HIV measure (intact DNA, defective DNA, or plasma RNA), the 430 inflection point, τ , was estimated by minimizing the model's mean absolute prediction error. Candidate τ values were tested iteratively (from 0 weeks to 24 weeks) and the mean absolute 431 errors (MAEs) were estimated using leave-one-out cross-validation: 432

$$MAE(\tau) = \sum_{i,t} \left| \log_{10}(I_{it}) - \log_{10}\left(\hat{I}_{it}^{(-i)}\right) \right|, \#(2)$$

where $\hat{I}_{it}^{(-i)}$ reflected the predicted HIV DNA counts for participant *i* at time *t* using the model fit for each participant (excluding participant *i*). Inflection points for the triphasic model were estimated similarly. We then compared the fit of various models using Akaike information criteria (AIC).

To facilitate the interpretability of our results and to allow direct comparison with prior reports,^{3,52,58} we estimated decay half-lives, and their confidence intervals for each phase of decay, using the multivariate delta method.⁸⁶ For example, the half-life in the first decay phase, from model (1), was calculated as

$$t_{1/2}(E_i) = -\frac{0.25 \log_{10}(2)}{\beta_1 + \beta_2 E_i} = -\frac{0.25 \log_{10}(2)}{\beta_1} + \frac{0.25 \log_{10}(2) \beta_2 E_i}{\beta_1^2} + O(E_i^2), \#(3)$$

where the second equality reflected the degree-one Taylor series about $E_i = 0$. We centered E_i prior to model estimation to justify the degree-one Taylor series approximation of half-life. Thus, we estimated the baseline $t_{1/2}$ as $g_1(\beta_1, \beta_3) = -0.25 \log_{10}(2) / \beta_1$ and the adjusted $t_{1/2}$ (for each week delay in ART initiation) as $g_2(\beta_1, \beta_2) = 0.25 \log_{10}(2) \beta_2 / \beta_1^2$. Finally, we included our estimated model parameters into the delta method to obtain half-life estimates:

$$\sqrt{n} \left(\begin{bmatrix} g_1(\widehat{\beta_1}, \widehat{\beta_2}) \\ g_2(\widehat{\beta_1}, \widehat{\beta_2}) \end{bmatrix} - \begin{bmatrix} g_1(\beta_1, \beta_2) \\ g_2(\beta_1, \beta_2) \end{bmatrix} \right) \stackrel{d}{\to} N \left(\begin{pmatrix} 0 \\ 0 \end{pmatrix}, J \Sigma J^T \right) \#(4)$$
$$J = 0.25 \log_{10}(2) \begin{bmatrix} \frac{1}{\beta_1^2} & 0 \\ -2\frac{\beta_2}{\beta_1^2} & \frac{1}{\beta_1^2} \end{bmatrix}, \#(5)$$

where Σ reflected the covariance between β_1 and β_2 , and *J* was the Jacobian matrix of $g(\beta_1, \beta_2)$. For further interpretability, we calculated the percent decay/week (prior to τ) using the transformation $h(\beta_1) = -100 (2^{\beta_1} - 1)$. Similar calculations were performed for the second decay phase using β_3 and β_4 instead of β_1 and β_2 .

We performed further validation of our proposed HIV DNA (intact, defective) and HIV 450 451 RNA (plasma) decay models against known clinical factors associated with HIV reservoir size.^{23,24,34,42,43} Focusing on the clinical covariates of (i) initial CD4+ T cell count, (ii) pre-ART 452 453 viral load, and (iii) timing of ART initiation (days from HIV infection to ART start date), we 454 performed bootstrapping predictions by resampling and generating 300 new participants. The final HIV decay models (intact DNA, defective DNA, plasma RNA) were used to predict decay 455 456 patterns for each resampled (bootstrapped) participant. For data visualization, we partitioned the resampled data into tertiles to demonstrate average predicted decay patterns by tertiles of 457 each clinical predictor. 458

Table 1. UCSF Treat Acute HIV Study Population. Medians (with interquartile ranges) or frequencies

(with percentages) are shown.

	N = 67
Timing of ART initiation (days from date of detected HIV infection to ART start date)	31.0 (22.0 – 88.5)
Initial CD4+ T-cell count (cells/mm ³)	505 (350 – 670)
Pre-ART plasma HIV RNA (log ₁₀ copies)	4.85 (3.69 – 5.65)
Age	30.0 (25.5 – 38.0)
Gender (self-reported)	
Male	65 (97.0%)
Cisgender Female	1 (1.50%)
Transgender Female	1 (1.50%)
Race/ethnicity (self-reported)	
White	22 (32.8%)
Latinx	20 (29.9%)
Asian	14 (20.9%)
Black	10 (14.9%)
Other	1 (1.5%)
Prior pre-exposure prophylaxis (PrEP)	29 (43.3%)
HIV acquisition/PrEP overlap <10 days	15 (22.4%)
PrEP initiated but already acquired HIV	8 (11.9%)
HIV acquired on PrEP ^a	6 (9.0%)
Referral HIV testing sites	
San Francisco Department Public Health (%)	28 (41.8%)
Community-Based Organization (%)	29 (43.2%)
Private Health Clinics (%)	10 (14.9%)
Unstably housed	2 (3.0%)

^a For participants with HIV acquired on PrEP: median baseline plasma log₁₀HIV RNA was 2.2 copies/mL.

Fig. 1: The distribution of study participants in the UCSF Treat Acute HIV cohort. A total of 67 participants met inclusion criteria for acute HIV, defined as <100 days since the estimated date of detected HIV infection (EDDI) using the Infection Dating Tool (https://tools.incidence-estimation.org/idt/); these estimates were then used to estimate acute HIV Fiebig stages (a).^{47,48} The majority of the cohort was of non-White self-reported race/ethnicity, consistent with national trends for people incident acute HIV (b).⁴⁹



a.

b.

Fig. 2: Semiparametric monophasic, biphasic, and triphasic generalized additive models of HIV reservoir decay during weeks 0-24. We performed bootstrapping to estimate the Akaike information criteria (AIC) value and 95% confidence intervals and compared monophasic, biphasic, and triphasic models for both HIV intact (left panels) and defective (right panels) DNA assays (a). Using the triphasic models for HIV intact (left panel) and defective (right panel) DNA, we then determined the optimal inflection point(s), τ , by minimizing the predicted mean absolute error (MAE; top panels) using leave-one-out cross-validation or the predicted mean squared error (MSE; bottom panels) (b). Red dots denote the optimal inflection point(s), τ , for each model and prediction loss metric. For HIV intact DNA, the first (x-axis) and second (y-axis) inflection points were relatively similar, suggesting that a single inflection point (x-axis) was close to zero, this again suggested that a biphasic model reasonably described the data.

a.

HIV Reservoir	Monophasic (95% CI)	Biphasic (95% CI)	Triphasic (95% CI)
Intact DNA	886 (722, 1023)	797 (595, 968)	796 (597, 965)
Defective DNA	1426 (1344, 1504)	1268 (1183, 1343)	1272 (1188, 1348)

b.



Fig. 3 Determination of optimal inflection points for HIV intact and defective DNA biphasic decay

models. Using the biphasic models for HIV intact (left panel) and defective (right panel) DNA, we then determined the optimal inflection point(s), τ , by minimizing the predicted mean absolute error (MAE; top panels) using leave-one-out cross-validation or the predicted mean squared error (MSE; bottom panels) (b). An inflection point of $\tau = 5$ weeks (vertical dashed line) best fit decay patterns for both HIV intact (left panels) and defective (right panels) DNA. Red dots denote the best τ for each model and prediction error metric.



Fig. 4 Predicted decay patterns of HIV intact and defective DNA during acute treated HIV

from weeks 0-24. Decay patterns for observed (thin grey lines) HIV intact and total defective (a), as well as 3' and 5' defective (b) DNA closely fit with average model predictions (thick black lines). Sampling timepoints are labeled on the x-axis (including a week 2 study visit during which confirmatory HIV test results were disclosed). We estimated average predicted participant decay rates by taking the mean of (estimated time between HIV infection and ART initiation),

(initial CD4+ T cell count), and (\log_{10} pre-ART plasma viral load) across participants from final models.



Fig. 5 HIV intact and defective DNA decay patterns were associated with known clinical factors associated with HIV reservoir size. The observed HIV DNA data are shown as thin grey lines for each participant, while the decay pattern for the model-predicted average participant is shown as the thick black lines. Biphasic decay patterns for HIV intact (left panel) and combined defective (3' plus 5', right panel) were faster among participants initiating ART earlier (<30 days vs. 30-100 days) (a), with higher initial CD4+ T cell counts (shown by tertiles) (b), and lower pre-ART viral load (shown by tertiles) (c).

a.



b.



Initial CD4+ T Cell Count (Cells/mm³) - [149,361] - (361,593] - (593,1131]

C.



Log₁₀ Pre-ART Viral Load (Cells/mL) - [1.3,4.43] - (4.43,5.45] - (5.45,7]

Fig. 6 Predicted HIV intact and defective DNA decay rates, by tertiles of clinical factors associated with HIV reservoir size. We performed bootstrapping to estimate the average predicted decay rates of HIV intact (left panels) and defective (right panels) DNA, stratified by tertiles of known clinical factors associated with HIV reservoir size: timing of ART initiation (a), initial CD4+ T cell count (b), and pre-ART viral load (c).

6 **a**.



- 10
- 11

C.



15 **REFERENCES**

- 16 1 Chun, T. W. et al. Rebound of plasma viremia following cessation of antiretroviral
- 17 therapy despite profoundly low levels of HIV reservoir: implications for
- 18 eradication. *AIDS* **24**, 2803-2808 (2010).
- 19 https://doi.org:10.1097/QAD.0b013e328340a239
- 20 2 Hocqueloux, L. *et al.* Long-term immunovirologic control following antiretroviral
- 21 therapy interruption in patients treated at the time of primary HIV-1 infection.
- 22 AIDS 24, 1598-1601 (2010). <u>https://doi.org:10.1097/qad.0b013e32833b61ba</u>
- 23 3 White, J. A. *et al.* Complex decay dynamics of HIV virions, intact and defective
- proviruses, and 2LTR circles following initiation of antiretroviral therapy. *Proc Natl*
- 25 Acad Sci U S A 119 (2022). <u>https://doi.org:10.1073/pnas.2120326119</u>
- 26 4 Perelson, A. S. et al. Decay characteristics of HIV-1-infected compartments
- 27 during combination therapy. *Nature* **387**, 188-191 (1997).
- 28 https://doi.org:10.1038/387188a0
- 5 Kwon, K. J. & Siliciano, R. F. HIV persistence: clonal expansion of cells in the
- 30 latent reservoir. *J Clin Invest* **127**, 2536-2538 (2017).
- 31 https://doi.org:10.1172/JCI95329
- 32 6 Finzi, D. & Siliciano, R. F. Viral dynamics in HIV-1 infection. *Cell* **93**, 665-671
- 33 (1998). <u>https://doi.org:10.1016/s0092-8674(00)81427-0</u>
- 34 7 Chomont, N. *et al.* HIV reservoir size and persistence are driven by T cell survival
- and homeostatic proliferation. *Nature medicine* **15**, 893-900 (2009).
- 36 <u>https://doi.org:10.1038/nm.1972</u>

- 37 8 Yukl, S. A. *et al.* Differences in HIV burden and immune activation within the gut
- of HIV-positive patients receiving suppressive antiretroviral therapy. *The Journal*
- 39 of infectious diseases **202**, 1553-1561 (2010). <u>https://doi.org:10.1086/656722</u>
- 40 9 Archin, N. M. *et al.* Administration of vorinostat disrupts HIV-1 latency in patients
- 41 on antiretroviral therapy. *Nature* **487**, 482-485 (2012).
- 42 https://doi.org:10.1038/nature11286
- 43 10 Elliott, J. H. et al. Short-term administration of disulfiram for reversal of latent HIV
- 44 infection: a phase 2 dose-escalation study. *Lancet HIV* **2**, e520-529 (2015).
- 45 <u>https://doi.org:10.1016/S2352-3018(15)00226-X</u>
- 46 11 Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-
- 47 virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a
- 48 phase 1/2, single group, clinical trial. *Lancet HIV* **1**, e13-21 (2014).
- 49 <u>https://doi.org:10.1016/S2352-3018(14)70014-1</u>
- 50 12 Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in
- 51 HIV-infected patients on suppressive antiretroviral therapy. *PLoS pathogens* **10**,
- 52 e1004473 (2014). <u>https://doi.org:10.1371/journal.ppat.1004473</u>
- 53 13 Gay, C. L. et al. Assessing the impact of AGS-004, a dendritic cell-based
- 54 immunotherapy, and vorinostat on persistent HIV-1 Infection. Sci Rep 10, 5134
- 55 (2020). <u>https://doi.org:10.1038/s41598-020-61878-3</u>
- 56 14 Fidler, S. et al. Antiretroviral therapy alone versus antiretroviral therapy with a
- 57 kick and kill approach, on measures of the HIV reservoir in participants with
- recent HIV infection (the RIVER trial): a phase 2, randomised trial. *Lancet* **395**,
- 59 888-898 (2020). <u>https://doi.org:10.1016/S0140-6736(19)32990-3</u>

- 60 15 Gutierrez, C. *et al.* Bryostatin-1 for latent virus reactivation in HIV-infected
- 61 patients on antiretroviral therapy. *AIDS* **30**, 1385-1392 (2016).
- 62 https://doi.org:10.1097/QAD.00000000001064
- 16 Vibholm, L. et al. Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts
- 64 Innate Immunity and Plasma Viremia in Individuals With Human
- Immunodeficiency Virus Infection. *Clin Infect Dis* **64**, 1686-1695 (2017).
- 66 <u>https://doi.org:10.1093/cid/cix201</u>
- 17 Riddler, S. A. *et al.* Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune
- 68 Activation in Virally Suppressed Adults Living With Human Immunodeficiency
- 69 Virus-1. *Clin Infect Dis* **72**, e815-e824 (2021).
- 70 https://doi.org:10.1093/cid/ciaa1534
- 71 18 Elliott, J. H. et al. Short-term administration of disulfiram for reversal of latent HIV
- infection: a phase 2 dose-escalation study. *Lancet HIV* **2**, e520-529 (2015).
- 73 <u>https://doi.org:10.1016/S2352-3018(15)00226-X</u>
- 19 Bar, K. J. et al. Effect of HIV Antibody VRC01 on Viral Rebound after Treatment
- 75 Interruption. *N Engl J Med* **375**, 2037-2050 (2016).
- 76 https://doi.org:10.1056/NEJMoa1608243
- 77 20 Gunst, J. D. et al. Early intervention with 3BNC117 and romidepsin at
- antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized
- 79 trial. Nat Med 28, 2424-2435 (2022). <u>https://doi.org:10.1038/s41591-022-02023-7</u>
- 80 21 Gunst, J. D. et al. in Conference on Retroviruses and Opportunistic Infections.

- 81 22 Namazi, G. et al. The Control of HIV After Antiretroviral Medication Pause
- 82 (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J
- 83 Infect Dis **218**, 1954-1963 (2018). <u>https://doi.org:10.1093/infdis/jiy479</u>
- 84 23 Archin, N. M. et al. Immediate antiviral therapy appears to restrict resting CD4+
- cell HIV-1 infection without accelerating the decay of latent infection. *Proc Natl*
- 86 Acad Sci U S A **109**, 9523-9528 (2012).
- 87 <u>https://doi.org:10.1073/pnas.1120248109</u>
- 88 24 Buzon, M. J. et al. Long-term antiretroviral treatment initiated at primary HIV-1
- 89 infection affects the size, composition, and decay kinetics of the reservoir of HIV-
- 90 1-infected CD4 T cells. *J Virol* **88**, 10056-10065 (2014).
- 91 https://doi.org:10.1128/JVI.01046-14
- 92 25 Chun, T. W. *et al.* Early establishment of a pool of latently infected, resting
- 93 CD4(+) T cells during primary HIV-1 infection. *Proc Natl Acad Sci U S A* **95**,

94 8869-8873 (1998). <u>https://doi.org:10.1073/pnas.95.15.8869</u>

- 95 26 Strain, M. C. et al. Effect of treatment, during primary infection, on establishment
- and clearance of cellular reservoirs of HIV-1. *J Infect Dis* **191**, 1410-1418 (2005).
- 97 <u>https://doi.org:10.1086/428777</u>
- 98 27 Hocqueloux, L., Saez-Cirion, A. & Rouzioux, C. Immunovirologic control 24
- 99 months after interruption of antiretroviral therapy initiated close to HIV
- 100 seroconversion. *JAMA Intern Med* **173**, 475-476 (2013).
- 101 https://doi.org:10.1001/jamainternmed.2013.2176
- 102 28 Ananworanich, J. et al. Virological and immunological characteristics of HIV-
- infected individuals at the earliest stage of infection. *J Virus Erad* **2**, 43-48 (2016).

- 104 29 Ananworanich, J. et al. Impact of multi-targeted antiretroviral treatment on gut T
- 105 cell depletion and HIV reservoir seeding during acute HIV infection. *PLoS One* **7**,
- 106 e33948 (2012). <u>https://doi.org:10.1371/journal.pone.0033948</u>
- 107 30 Deleage, C. et al. Impact of early cART in the gut during acute HIV infection. JCI
- 108 Insight 1 (2016). <u>https://doi.org:10.1172/jci.insight.87065</u>
- 109 31 Takata, H. et al. Long-term antiretroviral therapy initiated in acute HIV infection
- prevents residual dysfunction of HIV-specific CD8(+) T cells. *EBioMedicine* 84,
- 111 104253 (2022). <u>https://doi.org:10.1016/j.ebiom.2022.104253</u>
- 112 32 Oxenius, A. *et al.* Early highly active antiretroviral therapy for acute HIV-1
- infection preserves immune function of CD8+ and CD4+ T lymphocytes. *Proc*
- 114 Natl Acad Sci U S A **97**, 3382-3387 (2000).
- 115 <u>https://doi.org:10.1073/pnas.97.7.3382</u>
- 116 33 Streeck, H. et al. Immunological and virological impact of highly active
- antiretroviral therapy initiated during acute HIV-1 infection. J Infect Dis **194**, 734-
- 118 739 (2006). <u>https://doi.org:10.1086/503811</u>
- 119 34 Peluso, M. J. et al. Differential decay of intact and defective proviral DNA in HIV-
- 120 1-infected individuals on suppressive antiretroviral therapy. *JCI Insight* **5** (2020).
- 121 <u>https://doi.org:10.1172/jci.insight.132997</u>
- 122 35 Gandhi, R. T. *et al.* Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral
- 123 Therapy. J Infect Dis 223, 225-233 (2021). <u>https://doi.org:10.1093/infdis/jiaa532</u>
- 124 36 Gandhi, R. T. et al. Varied Patterns of Decay of Intact Human Immunodeficiency
- 125 Virus Type 1 Proviruses Over 2 Decades of Antiretroviral Therapy. *J Infect Dis*
- 126 **227**, 1376-1380 (2023). <u>https://doi.org:10.1093/infdis/jiad039</u>

- 127 37 Antar, A. A. *et al.* Longitudinal study reveals HIV-1-infected CD4+ T cell
- dynamics during long-term antiretroviral therapy. J Clin Invest **130**, 3543-3559
- 129 (2020). <u>https://doi.org:10.1172/JCI135953</u>
- 130 38 Leyre, L. *et al.* Abundant HIV-infected cells in blood and tissues are rapidly
- 131 cleared upon ART initiation during acute HIV infection. *Sci Transl Med* **12** (2020).
- 132 https://doi.org:10.1126/scitranslmed.aav3491
- 133 39 Massanella, M. *et al.* Long-term effects of early antiretroviral initiation on HIV
- reservoir markers: a longitudinal analysis of the MERLIN clinical study. Lancet
- 135 *Microbe* **2**, e198-e209 (2021). <u>https://doi.org:10.1016/S2666-5247(21)00010-0</u>
- 136 40 De Clercq, J. *et al.* Longitudinal patterns of inflammatory mediators after acute
- HIV infection correlate to intact and total reservoir. *Front Immunol* **14**, 1337316
- 138 (2023). <u>https://doi.org:10.3389/fimmu.2023.1337316</u>
- 139 41 Shi, L. et al. in International AIDS Society Conference on HIV Science.
- 140 42 Ananworanich, J. et al. HIV DNA Set Point is Rapidly Established in Acute HIV
- 141 Infection and Dramatically Reduced by Early ART. *EBioMedicine* **11**, 68-72
- 142 (2016). <u>https://doi.org:10.1016/j.ebiom.2016.07.024</u>
- 143 43 Crowell, T. A. *et al.* Virologic failure is uncommon after treatment initiation during
- 144 acute HIV infection. *AIDS* **30**, 1943-1950 (2016).
- 145 <u>https://doi.org:10.1097/QAD.00000000001148</u>
- Lee SA, H. T., Gandhi M, Coffey S, Harting H, Hoh R, Peluso MJ, Siegel D,
- 147 Crouch P, Scott H, Cohen SD, Sachdev D, Bacon O, Busch M, Pilcher C,
- Buchbinder S, Havlir DV, Deeks SG. in *International AIDS Society Conference*.

- 149 45 Grebe, E. *et al.* Interpreting HIV diagnostic histories into infection time estimates:
- analytical framework and online tool. *BMC Infect Dis* **19**, 894 (2019).
- 151 <u>https://doi.org:10.1186/s12879-019-4543-9</u>
- 152 46 Facente, S. N. et al. Estimated dates of detectable infection (EDDIs) as an
- improvement upon Fiebig staging for HIV infection dating. *Epidemiol Infect* **148**,
- 154 e53 (2020). <u>https://doi.org:10.1017/S0950268820000503</u>
- 155 47 Fiebig, E. W. et al. Dynamics of HIV viremia and antibody seroconversion in
- plasma donors: implications for diagnosis and staging of primary HIV infection.
- 157 *AIDS* **17**, 1871-1879 (2003).
- 158 <u>https://doi.org:10.1097/01.aids.0000076308.76477.b8</u>
- 159 48 Keele, B. F. *et al.* Identification and characterization of transmitted and early
- 160 founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci U S A*
- 161 **105**, 7552-7557 (2008). <u>https://doi.org:10.1073/pnas.0802203105</u>
- 162 49 Prevention., C. f. D. C. a. HIV Surveillance Report.
- 163 <u>http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html</u>. Published May 2022.
- 164 Accessed Nov 2, 2023., (2020).
- 165 50 Buchbinder, S. P. & Havlir, D. V. Getting to Zero San Francisco: A Collective
- 166 Impact Approach. J Acquir Immune Defic Syndr 82 Suppl 3, S176-S182 (2019).
- 167 <u>https://doi.org:10.1097/QAI.000000000002200</u>
- 168 51 Cohen, S. E. et al. Acquisition of tenofovir-susceptible, emtricitabine-resistant
- 169 HIV despite high adherence to daily pre-exposure prophylaxis: a case report.
- 170 *Lancet HIV* (2018). <u>https://doi.org:10.1016/S2352-3018(18)30288-1</u>

- 171 52 Andrade, A. et al. Three distinct phases of HIV-1 RNA decay in treatment-naive
- patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect
- 173 *Dis* **208**, 884-891 (2013). <u>https://doi.org:10.1093/infdis/jit272</u>
- 174 53 Raffi, F. et al. Once-daily dolutegravir versus twice-daily raltegravir in
- antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results
- from a randomised, double-blind, non-inferiority trial. *Lancet Infect Dis* **13**, 927-
- 177 935 (2013). <u>https://doi.org:10.1016/S1473-3099(13)70257-3</u>
- 178 54 Powderly, W. G. Integrase inhibitors in the treatment of HIV-1 infection. J
- 179 Antimicrob Chemother 65, 2485-2488 (2010). <u>https://doi.org:10.1093/jac/dkq350</u>
- 180 55 Reeves, D. B. et al. Impact of misclassified defective proviruses on HIV reservoir
- 181 measurements. *Nat Commun* **14**, 4186 (2023). <u>https://doi.org:10.1038/s41467-</u>
- 182 <u>023-39837-z</u>
- 183 56 Reeves, D. B. et al. A majority of HIV persistence during antiretroviral therapy is
- due to infected cell proliferation. *Nat Commun* **9**, 4811 (2018).
- 185 <u>https://doi.org:10.1038/s41467-018-06843-5</u>
- 186 57 McMyn, N. F. et al. The latent reservoir of inducible, infectious HIV-1 does not
- decrease despite decades of antiretroviral therapy. *J Clin Invest* **133** (2023).
- 188 <u>https://doi.org:10.1172/JCI171554</u>
- 189 58 Massanella, M. *et al.* Long-term effects of early antiretroviral initiation on HIV
- 190 reservoir markers: a longitudinal analysis of the MERLIN clinical study. Lancet
- 191 *Microbe* **2**, e198-e209 (2021). <u>https://doi.org:10.1016/s2666-5247(21)00010-0</u>

- 192 59 Fromentin, R. et al. CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute
- to HIV Persistence during ART. *PLoS Pathog* **12**, e1005761 (2016).
- 194 <u>https://doi.org:10.1371/journal.ppat.1005761</u>
- 195 60 Fromentin, R. et al. PD-1 blockade potentiates HIV latency reversal ex vivo in
- 196 CD4(+) T cells from ART-suppressed individuals. *Nat Commun* **10**, 814 (2019).
- 197 <u>https://doi.org:10.1038/s41467-019-08798-7</u>
- 198 61 Murray, J. M., Kelleher, A. D. & Cooper, D. A. Timing of the components of the
- 199 HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected
- 200 individuals. J Virol 85, 10798-10805 (2011). <u>https://doi.org:10.1128/JVI.05095-11</u>
- Gilmore, J. B., Kelleher, A. D., Cooper, D. A. & Murray, J. M. Explaining the
- 202 determinants of first phase HIV decay dynamics through the effects of stage-
- dependent drug action. *PLoS Comput Biol* **9**, e1002971 (2013).
- 204 https://doi.org:10.1371/journal.pcbi.1002971
- 205 63 Perelson, A. S., Neumann, A. U., Markowitz, M., Leonard, J. M. & Ho, D. D. HIV-
- 1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral
- 207 generation time. *Science* **271**, 1582-1586 (1996).
- 208 <u>https://doi.org:10.1126/science.271.5255.1582</u>
- 209 64 Markowitz, M. et al. A novel antiviral intervention results in more accurate
- 210 assessment of human immunodeficiency virus type 1 replication dynamics and T-
- cell decay in vivo. *J Virol* **77**, 5037-5038 (2003).
- 212 <u>https://doi.org:10.1128/jvi.77.8.5037-5038.2003</u>

- 213 65 Shan, L. *et al.* Transcriptional Reprogramming during Effector-to-Memory
- 214 Transition Renders CD4(+) T Cells Permissive for Latent HIV-1 Infection.
- 215 Immunity 47, 766-775 e763 (2017). <u>https://doi.org:10.1016/j.immuni.2017.09.014</u>
- 216 66 De Boer, R. J., Homann, D. & Perelson, A. S. Different dynamics of CD4+ and
- 217 CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus
- 218 infection. *J Immunol* **171**, 3928-3935 (2003).
- 219 https://doi.org:10.4049/jimmunol.171.8.3928
- 220 67 Zhan, Y., Carrington, E. M., Zhang, Y., Heinzel, S. & Lew, A. M. Life and Death
- of Activated T Cells: How Are They Different from Naive T Cells? *Front Immunol*
- 222 **8**, 1809 (2017). <u>https://doi.org:10.3389/fimmu.2017.01809</u>
- 223 68 Siliciano, J. D. *et al.* Long-term follow-up studies confirm the stability of the latent
- reservoir for HIV-1 in resting CD4+ T cells. *Nat Med* **9**, 727-728 (2003).
- 225 https://doi.org:10.1038/nm880
- 226 69 Crooks, A. M. *et al.* Precise Quantitation of the Latent HIV-1 Reservoir:
- Implications for Eradication Strategies. *J Infect Dis* **212**, 1361-1365 (2015).
- 228 https://doi.org:10.1093/infdis/jiv218
- 229 70 Vandergeeten, C. et al. Cross-clade ultrasensitive PCR-based assays to
- measure HIV persistence in large-cohort studies. *J Virol* **88**, 12385-12396 (2014).
- 231 <u>https://doi.org:10.1128/JVI.00609-14</u>
- 232 71 Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active
- antiretroviral therapy. *Science* **278**, 1295-1300 (1997).
- 234 <u>https://doi.org:10.1126/science.278.5341.1295</u>

- 235 72 Procopio, F. A. *et al.* A Novel Assay to Measure the Magnitude of the Inducible
- 236 Viral Reservoir in HIV-infected Individuals. *EBioMedicine* **2**, 872-881 (2015).
- 237 <u>https://doi.org:10.1016/j.ebiom.2015.06.019</u>
- Ho, Y. C. *et al.* Replication-competent noninduced proviruses in the latent
- reservoir increase barrier to HIV-1 cure. *Cell* **155**, 540-551 (2013).
- 240 <u>https://doi.org:10.1016/j.cell.2013.09.020</u>
- 241 74 Eriksson, S. et al. Comparative analysis of measures of viral reservoirs in HIV-1
- eradication studies. *PLoS pathogens* **9**, e1003174 (2013).
- 243 <u>https://doi.org:10.1371/journal.ppat.1003174</u>
- 244 75 Pollack, R. A. *et al.* Defective HIV-1 Proviruses Are Expressed and Can Be
- Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.
- 246 *Cell Host Microbe* **21**, 494-506 e494 (2017).
- 247 https://doi.org:10.1016/j.chom.2017.03.008
- 248 76 Simon, V. & Ho, D. D. HIV-1 dynamics in vivo: implications for therapy. *Nat Rev*
- 249 *Microbiol* **1**, 181-190 (2003). <u>https://doi.org:10.1038/nrmicro772</u>
- 250 77 Siliciano, J. D. et al. Long-term follow-up studies confirm the stability of the latent
- reservoir for HIV-1 in resting CD4+ T cells. *Nature medicine* **9**, 727-728 (2003).
- 252 <u>https://doi.org:10.1038/nm880</u>
- 253 78 Pinzone, M. R. *et al.* Longitudinal HIV sequencing reveals reservoir expression
- leading to decay which is obscured by clonal expansion. *Nat Commun* **10**, 728
- 255 (2019). <u>https://doi.org:10.1038/s41467-019-08431-7</u>

- 256 79 Gondim, M. V. P. *et al.* Heightened resistance to host type 1 interferons
- characterizes HIV-1 at transmission and after antiretroviral therapy interruption.
- 258 Sci Transl Med 13 (2021). <u>https://doi.org:10.1126/scitranslmed.abd8179</u>
- 80 Kinloch, N. N. et al. HIV-1 diversity considerations in the application of the Intact
- 260 Proviral DNA Assay (IPDA). *Nat Commun* **12**, 165 (2021).
- 261 <u>https://doi.org:10.1038/s41467-020-20442-3</u>
- 262 81 Whitney, J. B. *et al.* Rapid seeding of the viral reservoir prior to SIV viraemia in
- 263 rhesus monkeys. *Nature* **512**, 74-77 (2014). <u>https://doi.org:10.1038/nature13594</u>
- 82 Kumar, M. R. *et al.* Biphasic decay of intact SHIV genomes following initiation of
- 265 antiretroviral therapy complicates analysis of interventions targeting the reservoir.
- 266 Proc Natl Acad Sci U S A **120**, e2313209120 (2023).
- 267 <u>https://doi.org:10.1073/pnas.2313209120</u>
- 268 83 Martin, A. R. *et al.* Similar Frequency and Inducibility of Intact Human
- 269 Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. J Infect Dis
- 270 **224**, 258-268 (2021). <u>https://doi.org:10.1093/infdis/jiaa736</u>
- 271 84 Simonetti, F. R. *et al.* Intact proviral DNA assay analysis of large cohorts of
- 272 people with HIV provides a benchmark for the frequency and composition of
- 273 persistent proviral DNA. *Proc Natl Acad Sci U S A* **117**, 18692-18700 (2020).
- 274 <u>https://doi.org:10.1073/pnas.2006816117</u>
- 85 Bruner, K. M. et al. A quantitative approach for measuring the reservoir of latent
- 276 HIV-1 proviruses. *Nature* **566**, 120-125 (2019). <u>https://doi.org:10.1038/s41586-</u>
- 277 <u>019-0898-8</u>

- 278 86 Lehmann, E. L. & Casella, G. *Theory of point estimation*. Second edition. edn,
- 279 (Springer, 1998).

280

282 FIGURE LEGENDS

- Table 1. UCSF Treat Acute HIV Study Population. Medians (with interquartile ranges) or
 frequencies (with percentages) are shown.
- 285

Fig. 1: The distribution of study participants in the UCSF Treat Acute HIV cohort. A total of 67 participants met inclusion criteria for acute HIV, defined as <100 days since the estimated date of detected HIV infection (EDDI) using the Infection Dating Tool (https://tools.incidenceestimation.org/idt/); these estimates were then used to estimate acute HIV Fiebig stages (a).^{47,48} The majority of the cohort was of non-White self-reported race/ethnicity, consistent with national trends for people incident acute HIV (b).⁴⁹

292

293 Fig. 2: Semiparametric monophasic, biphasic, and triphasic generalized additive models of HIV reservoir decay during weeks 0-24. We performed bootstrapping to estimate the 294 Akaike information criteria (AIC) value and 95% confidence intervals and compared 295 monophasic, biphasic, and triphasic models for both HIV intact (left panels) and defective (right 296 297 panels) DNA assays (a). Using the triphasic models for HIV intact (left panel) and defective 298 (right panel) DNA, we then determined the optimal inflection point(s), τ , by minimizing the 299 predicted mean absolute error (MAE; top panels) using leave-one-out cross-validation or the predicted mean squared error (MSE; bottom panels) (b). Red dots denote the optimal inflection 300 point(s), τ , for each model and prediction loss metric. For HIV intact DNA, the first (x-axis) and 301 302 second (y-axis) inflection points were relatively similar, suggesting that a single inflection point -303 i.e., a biphasic model - adequately described the data. For HIV defective DNA, the first inflection point (x-axis) was close to zero, this again suggested that a biphasic model 304 305 reasonably described the data.

306

Fig. 3 Determination of optimal inflection points for HIV intact and defective DNA biphasic decay models. Using the biphasic models for HIV intact (left panel) and defective (right panel) DNA, we then determined the optimal inflection point(s), τ , by minimizing the predicted mean absolute error (MAE; top panels) using leave-one-out cross-validation or the predicted mean squared error (MSE; bottom panels) (b). An inflection point of $\tau = 5$ weeks (vertical dashed line) best fit decay patterns for both HIV intact (left panels) and defective (right panels) DNA. Red dots denote the best τ for each model and prediction error metric.

314

315 Fig. 4 Predicted decay patterns of HIV intact and defective DNA during acute treated HIV

from weeks 0-24. Decay patterns for observed (thin grey lines) HIV intact and total defective (a), as well as 3' and 5' defective (b) DNA closely fit with average model predictions (thick black lines). Sampling timepoints are labeled on the x-axis (including a week 2 study visit during which confirmatory HIV test results were disclosed). We estimated average predicted participant decay rates by taking the mean of E_i (estimated time between HIV infection and ART initiation), C_i (initial CD4+ T cell count), and V_i (log₁₀ pre-ART plasma viral load) across participants from final models.

323

Fig. 5 HIV intact and defective DNA decay patterns were associated with known clinical factors associated with HIV reservoir size. The observed HIV DNA data are shown as thin grey lines for each participant, while the decay pattern for the model-predicted average participant is shown as the thick black lines. Biphasic decay patterns for HIV intact (left panel) and combined defective (3' plus 5', right panel) were faster among participants initiating ART earlier (<30 days vs. 30-100 days) (a), with higher initial CD4+ T cell counts (shown by tertiles) (b), and lower pre-ART viral load (shown by tertiles) (c).

331

Fig. 6 Predicted HIV intact and defective DNA decay rates, by tertiles of clinical factors associated with HIV reservoir size. We performed bootstrapping to estimate the average predicted decay rates of HIV intact (left panels) and defective (right panels) DNA, stratified by tertiles of known clinical factors associated with HIV reservoir size: timing of ART initiation (a), initial CD4+ T cell count (b), and pre-ART viral load (c).

337

Supplementary Fig. 1: The UCSF Treat Acute HIV cohort study participants. A total of 67 participants met inclusion criteria for acute HIV, defined as <100 days since the estimated date of detected HIV infection (EDDI) using the Infection Dating Tool (<u>https://tools.incidence-</u> estimation.org/idt/). The numbers of study participants by Fiebig stages (I-V) of HIV recency are also shown (https://doi.org:10.1097/01.aids.0000076308.76477.b8). PrEP = Pre-exposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).

344

Supplementary Fig. 2: Calculation of estimated dates of detected HIV infection. The estimated dates of detected HIV infection (EDDI), along with a "confidence interval" for early probable (EP-EDDI) and late probable (LP-EDDI) dates, were calculated using participants' clinical test results as well as baseline study visit confirmatory assay results.

349

Supplementary Fig. 3: HIV-1/2 test results for study participants. The proportion of study participants with either negative and/or indeterminate test results for HIV-1/2 p24 antigen/antibody assay (Architect) (a) and HIV-1/2 differentiation (Geenius) antibody assay (b) at baseline study visit were consistent with rates with our San Francisco Department of Public Health rates (27% and 28%, respectively).

355

Supplementary Fig. 4: HIV intact and defective DNA decay patterns by self-reported gender and prior PrEP use. Observed HIV intact and defective DNA data, highlighting the one cisgender female (yellow line) and one transgender female (blue line) participants (a). Participants reporting PrEP use within 10 days of HIV diagnosis fell into two categories: 6 participants who acquired HIV while already taking PrEP (yellow lines), and 8 participants who were found to already have acquired HIV at the time of PrEP initiation (blue lines). All other study participants are shown as grey lines.

363

Supplementary Fig. 5: Fine tuning of biphasic decay model inflection points from weeks 364 **0-52.** A total of 65.7% of the study participants continued in follow-up beyond 24 weeks. We 365 further refined our estimates for the inflection point, τ , by testing sequential half-week windows 366 from 0 to 52 weeks and comparing the minimum prediction error using the leave-one-out mean 367 absolute error (MAE, upper panels) or the leave-one-out mean squared error (MSE, lower 368 369 panels). An inflection point of $\tau = 5$ weeks (vertical dashed line) remained the best fit decay 370 pattern for both HIV intact (left panels) and defective (right panels) DNA out to 52 weeks of ART. Red dots denote the best τ for each model and prediction error metric. 371

372

Supplementary Table 1. Model estimates for HIV intact and defective DNA reservoir decay rates during acute treated HIV. Slope and half-life (t_{1/2}) estimates of HIV intact and defective decay rates for unadjusted (a-b) and adjusted models (b-c) during frequently sampled timepoints (weeks 0-24; a, c) and extended out to one year (weeks 0-52; b, d). Adjusted models included covariates for initial CD4+ T cell count, pre-ART HIV RNA, and timing of ART initiation.

379 Supplementary Fig. 6: Predicted decay patterns of HIV intact and defective DNA during 380 acute treated HIV from weeks 0-52. A total of 65.7% of the study participants continued in

follow-up beyond 24 weeks. Decay patterns for observed (thin grey lines) HIV intact (left panel) and total defective (right panel) DNA closely fit with average model predictions (thick black lines). Sampling timepoints are labeled on the x-axis (including a week 2 study visit during which confirmatory HIV test results were disclosed). Average predicted participant predictions were made by taking the mean of E_i (estimated time between HIV infection and ART initiation), C_i (initial CD4+ T cell count), and V_i (log₁₀ pre-ART plasma viral load) across participants from final models.

388

Supplementary Fig. 7: Predicted versus observed plots show good model performance for both HIV intact and defective DNA. Validation for the final models for intact and defective HIV DNA decay was initially performed by looking at the plots of predicted vs observed HIV DNA counts. These plots show that both models produce relatively unbiased estimates across the observed range of HIV DNA counts and that the residual variance in the defective reservoir is much higher than the intact reservoir. Red dashed line denotes the idealized fit where predicted values exactly equal observed values.

396

397 Supplementary Fig. 8: Sensitivity analyses estimating HIV intact and defective DNA 398 decay rates after excluding potential outlier clinical subgroups. The final model ($\tau = 5$ 399 weeks) was fit on three clinically interesting sub-populations to assess if the influence of potential outlier data. Separate models were fit that excluded (a) participants reporting prior 400 PrEP use (<10 days overlap between last PrEP use and estimated date of detected HIV 401 infection), (b) participants with plasma viral load "blips" (defined as a one-time viral load >1000 402 403 copies/mL or two consecutive viral loads >100 copies/mL between weeks 0-24), and (c) 404 participants with sudden increases in HIV intact DNA (defined as >50% increase between two consecutive measurements of HIV intact DNA during weeks 0-24). Models were fit using the 405 cohort data (grey lines), but not the potential outlier data (red lines). The resulting predicted 406

407 average participant HIV reservoir decay patterns are shown as thick black lines. Refer to 408 **Supplementary Table 1** to get the sample sizes and half-life estimates for each sensitivity 409 analysis.

410

411 Supplementary Fig. 9: Inflection point sensitivity analyses demonstrate some variability 412 when excluding populations of potential outliers. To test whether the final model inflection point selection of τ = 5 weeks was influenced by potential outlier data we performed τ estimation 413 on three clinically interesting sub-populations. Separate models were fit that excluded (a) 414 participants reporting prior PrEP use (<10 days overlap between last PrEP use and estimated 415 416 date of detected HIV infection), (b) participants with plasma viral load "blips" (defined as a one-417 time viral load >1000 copies/mL or two consecutive viral loads >100 copies/mL between weeks 0-24), and (c) participants with sudden increases in HIV intact DNA (defined as >50% increase 418 between two consecutive measurements of HIV intact DNA during weeks 0-24). A regular grid 419 420 of possible τ was used (0-26 weeks by half-week) and the leave-one-out cross-validation (LOOCV) mean absolute prediction error (MAE) was computed for each candidate τ . Red dots 421 denote the best τ for each model and prediction error metric and our selected inflection point (τ 422 = 5) is shown with a dashed vertical line. Refer to **Supplementary Table 1** to get the sample 423 size for each sensitivity analysis and to Supplementary Fig. 9 to see which patients are 424 425 excluded from each sensitivity analysis.

426

Supplementary Table 2. Sensitivity analyses of HIV intact and defective DNA reservoir decay rates during acute treated HIV. Slope and half-life estimates of HIV intact and defective decay rates after excluding participants reporting prior preexposure prophylaxis (PrEP) use within 10 days of estimated date of HIV infection (a), participants with plasma viral load "blips" (defined as a one-time viral load >1000 copies/mL or two consecutive viral loads >100

copies/mL between weeks 0-24) (b), and participants with sudden increases in HIV intact DNA
(defined as >50% increase between two consecutive measurements of HIV intact DNA during
weeks 0-24) (c). All models were adjusted for initial CD4+ T cell count, pre-ART HIV RNA, and
timing of ART initiation.

436

Supplementary Table 3. The effect of earlier ART initiation on HIV intact and defective
DNA decay rates. We performed bootstrapping to calculate the difference in half-life estimates
for HIV intact and defective DNA, with each week that ART is initiated earlier. All models were
adjusted for initial CD4+ T cell count and pre-ART HIV RNA.

441

Supplementary Table 4. The effect of higher initial CD4+ T cell count or lower pre-ART HIV RNA on HIV intact and defective DNA decay rates. We performed bootstrapping to calculate average half-life estimates for HIV intact and defective DNA for each quartile change in initial CD4+ T cell count or pre-ART HIV RNA. Models estimating the effect of initial CD4+ T cell count were adjusted for timing of ART initiation and pre-ART HIV RNA. Models estimating the effect of pre-ART HIV RNA were adjusted for timing of ART initiation and initial CD4+ T cell count.

449

450 Supplementary Fig. 10: Fitted spline models to estimate the effect of higher initial CD4+ T 451 cell count or lower pre-ART HIV RNA on HIV intact and defective DNA decay rates. Fitted 452 spline models (red lines) with corresponding 95% confidence intervals (blue dashed lines) are 453 shown for HIV intact DNA (a) and HIV defective (b) DNA. Plots are shown for pre-ART HIV RNA 454 (left panels) and initial CD4+ T cell count (right panels).

455

456 Supplementary Fig. 11: Semiparametric monophasic, biphasic, and triphasic generalized
 457 additive models of plasma HIV RNA decay during weeks 0-24. We performed bootstrapping

to estimate the Akaike information criteria (AIC) value and 95% confidence intervals and 458 459 compared monophasic, biphasic, and triphasic models for plasma HIV RNA (a). Using the 460 triphasic model for plasma HIV RNA, we then determined the optimal inflection point(s), τ , by minimizing the predicted mean absolute error (MAE: top panel) using leave-one-out cross-461 validation or the predicted mean squared error (MSE; bottom panel) (b). Red dots denote the 462 optimal inflection point(s), τ , for the model and loss metric. These analyses demonstrated an 463 inflection point at 0.5 weeks (red dot at x-axis) and 4 weeks (red dot at y-axis), suggesting that a 464 465 triphasic model best fit the data (b).

466

467 Supplementary Table 5. Model estimates of plasma HIV RNA decay rates during acute 468 treated HIV. Slope and half-life $(t_{1/2})$ estimates of plasma HIV RNA decay rates for models 469 adjusted for initial CD4+ T cell count and timing of ART initiation during frequently sampled 470 timepoints (weeks 0-24). Models included a random intercept for each participant. We calculated estimates for each phase of the final triphasic decay model: 0 to 0.5 weeks, 0.5-4 471 472 weeks, and 4-24 weeks. We did not observe a statistically significant decay of plasma HIV RNA 473 after week 4, given that the majority of participants had undetectable plasma HIV RNA levels after a median of 4.14 weeks on ART. 474

475

Supplementary Fig. 12: Predicted versus observed plots demonstrating model performance for plasma HIV RNA. Validation for the final model for plasma HIV RNA decay was initially performed by looking at the plots of predicted vs observed plasma HIV RNA counts. This plot shows that the triphasic model produces unbiased estimates for a large range of plasma HIV RNA counts. The model systematically underestimates very large plasma HIV RNA values and has high variability at very low plasma HIV RNA values (e.g., <40 copies/mL). Red dashed line denotes the idealized fit where predicted values exactly equal observed values.

483

Supplementary Fig. 13: Plasma HIV RNA decay patterns were associated with known clinical factors associated with HIV reservoir size. The observed plasma HIV RNA data are shown as thin grey lines for each participant. Plasma HIV RNA decay was faster among participants initiating ART earlier (<30 days vs. 30-100 days) (a) and with higher initial CD4+ T cell counts (shown by tertiles) (b).

489

Supplementary Fig. 14: Predicted plasma HIV RNA decay rates, by tertiles of clinical factors associated with HIV reservoir size. We performed bootstrapping to estimate the average predicted decay rates of plasma HIV RNA, stratified by known clinical factors associated with HIV reservoir size: timing of ART initiation (a) and initial CD4+ T cell count (b).

494

Supplementary Fig. 15: Fitted spline models to estimate the effect of higher initial CD4+ T
cell count on plasma HIV RNA decay rate. Fitted spline model (red line) with corresponding
95% confidence interval (blue dashed line) is shown for plasma HIV RNA in relation to initial
CD4+ T cell count.